Loading...
Please wait, while we are loading the content...
Similar Documents
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Wiseman, Gregory Aaron Gordon, Leo I. Multani, Pratik S. Witzig, Thomas E. Spies, Stewart Bartlett, Nancy L. Schilder, Russell Murray, James Saleh, Mansoor N. Allen, Roberta S. Grillo-López, Antonio J. White, Christine A. |
| Copyright Year | 2002 |
| Abstract | Mildly thrombocytopenic patients with relapsed or refractory low-grade non-Hodgkin lymphoma (NHL) have an increased risk of chemotherapy-induced myelosuppression following treatment. The safety and efficacy of radioimmunotherapy with a reduced dose of (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32 mCi [1.2 GBq]) was evaluated in 30 patients with mild thrombocytopenia (100-149 x 10(9) platelets/L) who had advanced, relapsed or refractory, low-grade, follicular, or transformed B-cell NHL. The ibritumomab tiuxetan regimen included an infusion of rituximab (250 mg/m(2)) and injection of (111)In ibritumomab tiuxetan (5 mCi [185 MBq]) for dosimetry evaluation, followed 1 week later with rituximab (250 mg/m(2)) and (90)Y ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]). Patients (median age, 61 years; 90% stage III/IV at study entry; 83% follicular lymphoma; and 67% with bone marrow involvement) had a median of 2 prior therapy regimens (range, 1-9). Estimated radiation-absorbed doses were well below the study-defined maximum allowable for all 30 patients. With the use of the International Workshop criteria for NHL response assessment, the overall response rate was 83% (37% complete response, 6.7% complete response unconfirmed, and 40% partial response). Kaplan-Meier estimated median time to progression (TTP) was 9.4 months (range, 1.7-24.6). In responders, Kaplan-Meier estimated median TTP was 12.6 months (range, 4.9-24.6), with 35% of data censored. Toxicity was primarily hematologic, transient, and reversible. The incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%, respectively. Reduced-dose ibritumomab tiuxetan is safe and well tolerated and has significant clinical activity in this patient population. |
| File Format | PDF HTM / HTML |
| DOI | 10.1182/blood.V99.12.4336 |
| Alternate Webpage(s) | http://www.bloodjournal.org/content/bloodjournal/99/12/4336.full.pdf?sso-checked=true |
| PubMed reference number | 12036859 |
| Alternate Webpage(s) | https://doi.org/10.1182/blood.V99.12.4336 |
| Journal | Medline |
| Volume Number | 99 |
| Issue Number | 12 |
| Journal | Blood |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
